p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells

被引：0
|
作者：
Barr, M. P. [1 ,2 ]
Batina, M. B. [1 ,2 ]
Cuffe, S. [1 ,2 ]
Finn, S. [1 ,2 ,3 ]
O'Byrne, K. J. [1 ,2 ,4 ]
机构：
[1] St James Hosp, Thorac Oncol Res Grp, Dublin, Ireland
[2] Univ Dublin Trinity Coll, Dublin 2, Ireland
[3] St James Hosp, Dept Histopathol, Dublin, Ireland
[4] Queensland Univ Technol, Canc & Ageing Res Program, Brisbane, Qld 4001, Australia
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
10.1016/S0169-5002(14)70003-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [21] Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer
    Maniwa, Y
    Yoshimura, M
    Obayashi, C
    Inaba, M
    Kiyooka, K
    Kanki, M
    Okita, Y
    CHEST, 2001, 120 (02) : 589 - 594
  • [22] p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland
    Niklinska, W
    Burzykowski, T
    Chyczewski, L
    Rusin, MR
    Furman, M
    Laudanski, J
    Chyczewska, E
    Sulik, M
    Niklinski, J
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2000, 9 (02) : 81 - 87
  • [23] Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer
    Tanaka, F
    Takata, T
    Yamada, T
    Yanagihara, K
    Otake, Y
    Miyahara, R
    Nakagawa, T
    Kawano, Y
    Ishikawa, S
    Inui, K
    Wada, H
    LUNG CANCER, 2002, 36 (01) : 27 - 32
  • [24] Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy
    Olivares-Hernandez, Alejandro
    del Barco Morillo, Edel
    Miramontes-Gonzalez, Jose Pablo
    Figuero-Perez, Luis
    Perez-Belmonte, Luis
    Martin-Vallejo, Javier
    Martin-Gomez, Teresa
    Escala-Cornejo, Roberto
    Vidal-Tocino, Rosario
    Bellido Hernandez, Lorena
    Gonzalez Sarmiento, Rogelio
    Ludena de la Cruz, Maria Dolores
    Cruz-Hernandez, Juan Jesus
    Parra Perez, Carmen
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (03):
  • [25] Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
    Van den Bossche, Jolien
    Domen, Andreas
    Peeters, Marc
    Deben, Christophe
    De Pauw, Ines
    Jacobs, Julie
    De Bruycker, Sven
    Specenier, Pol
    Pauwels, Patrick
    Vermorken, Jan Baptist
    Lardon, Filip
    Wouters, An
    CANCERS, 2019, 11 (12)
  • [26] P53 IN NON-SMALL-CELL LUNG-CANCER - RESPONSE
    MITSUDOMI, T
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (10) : 802 - 803
  • [27] Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines
    Duarte, Mariana Lemos
    de Moraes, Emanuela
    Pontes, Elizangela
    Schluckebier, Luciene
    de Moraes, Joyce Luana
    Hainaut, Pierre
    Ferreira, Carlos Gil
    CANCER LETTERS, 2009, 279 (01) : 57 - 64
  • [28] Teroxirone inhibited growth of human non-small cell lung cancer cells by activating p53
    Wang, Jing-Ping
    Lin, Kai-Han
    Liu, Chun-Yen
    Yu, Ya-Chu
    Wu, Pei-Tsun
    Chiu, Chien-Chih
    Su, Chun-Li
    Chen, Kwun-Min
    Fang, Kang
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2013, 273 (01) : 110 - 120
  • [29] Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer
    Johnson, EA
    Klimstra, DS
    Herndon, JE
    Catalano, E
    Canellos, GP
    Graziano, SL
    Kern, JA
    Green, MR
    CANCER INVESTIGATION, 2002, 20 (5-6) : 686 - 692
  • [30] p53 mutations predict non-small cell lung carcinoma response to radiotherapy
    Matsuzoe, D
    Hideshima, T
    Kimura, A
    Inada, K
    Watanabe, K
    Akita, Y
    Kawahara, K
    Shirakusa, T
    CANCER LETTERS, 1999, 135 (02) : 189 - 194
12345